PODCAST | Delving into Life Healthcare’s R14bn sale of Life Molecular Imaging
Mudiwa Gavaza speaks to Peter Wharton-Hood, CEO of Life Healthcare Group
15 January 2025 - 16:13
by Mudiwa Gavaza
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Peter Wharton-Hood. CEO of Life Healthcare Group. Picture: SUPPLIED.
Life Healthcare’s R14bn sale of Life Molecular Imaging is the focus of this edition of Business Day Spotlight.
Host Mudiwa Gavaza is joined by Peter Wharton-Hood, CEO of Life Healthcare Group.
This week, Life Healthcare, one of SA’s largest private hospital groups, signed a $750m (R13.9bn) deal to sell its Life Molecular Imaging (LMI) to Lantheus Radiopharmaceuticals UK, with the proceeds set to be returned to shareholders.
Outlining the rationale for the transaction, Wharton-Hood says “Life Healthcare is not a natural, long-term owner of LMI” and his company “will continue to participate in the future growth of LMI through a series of planned earnouts”.
Join the discussion:
With net proceeds of about $200m from the upfront payment, Wharton-Hood highlights that earnouts totalling a potential further $400m linked to future sales milestones are on the table.
Life Healthcare was expected to retain the commercial benefits awarded to LMI under the RM2 sub-licence agreement reached with Lantheus in June 2024, subject to agreeing on terms on which the net economic benefit of the agreement would be delivered to Life Healthcare before completion of the proposed transaction.
Through the discussion, Peter Wharton-Hood outlines the rationale for the transaction; Life Healthcare’s relationship with Lantheus; how the group is thinking around its current capital allocation; and investment in technology.
Wharton-Hood also highlights what the company is thinking regarding its portfolio and possible areas of investment.
Business Day Spotlight is a MultimediaLIVE Production.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
BUSINESS DAY SPOTLIGHT
PODCAST | Delving into Life Healthcare’s R14bn sale of Life Molecular Imaging
Mudiwa Gavaza speaks to Peter Wharton-Hood, CEO of Life Healthcare Group
Life Healthcare’s R14bn sale of Life Molecular Imaging is the focus of this edition of Business Day Spotlight.
Host Mudiwa Gavaza is joined by Peter Wharton-Hood, CEO of Life Healthcare Group.
This week, Life Healthcare, one of SA’s largest private hospital groups, signed a $750m (R13.9bn) deal to sell its Life Molecular Imaging (LMI) to Lantheus Radiopharmaceuticals UK, with the proceeds set to be returned to shareholders.
Outlining the rationale for the transaction, Wharton-Hood says “Life Healthcare is not a natural, long-term owner of LMI” and his company “will continue to participate in the future growth of LMI through a series of planned earnouts”.
Join the discussion:
With net proceeds of about $200m from the upfront payment, Wharton-Hood highlights that earnouts totalling a potential further $400m linked to future sales milestones are on the table.
Life Healthcare was expected to retain the commercial benefits awarded to LMI under the RM2 sub-licence agreement reached with Lantheus in June 2024, subject to agreeing on terms on which the net economic benefit of the agreement would be delivered to Life Healthcare before completion of the proposed transaction.
Through the discussion, Peter Wharton-Hood outlines the rationale for the transaction; Life Healthcare’s relationship with Lantheus; how the group is thinking around its current capital allocation; and investment in technology.
Wharton-Hood also highlights what the company is thinking regarding its portfolio and possible areas of investment.
Business Day Spotlight is a MultimediaLIVE Production.
Subscribe: iono.fm | Spotify | Apple Podcasts | Pocket Casts
Life Healthcare CEO says investors thought R14bn business was worth zero
PODCAST | Accessing healthcare in a tough SA economy
Healthcare dealmakers eye M&A resurgence in second Trump term
PODCAST | AfroCentric pushes for layered approach of AI in healthcare
AI has saved it billions, healthcare group AfroCentric says
PODCAST | Health tech promises new twist to prescriptions
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.